Curis Inc (CRIS) 1.73 $CRIS Curis to Present at Baird's

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Curis Inc (CRIS) 1.73 $CRIS

Curis to Present at Baird's 2016 Global Healthcare Conference
GlobeNewswire - Wed Aug 31, 6:00AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will present at Baird's 2016 Global Healthcare Conference on September 7, 2016, at 7:55 a.m. Eastern Time in New York City.
CRIS: 1.73 (+0.02)

Curis Reports Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 6:01AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today reported its financial results for the second quarter ended June 30, 2016.
CRIS: 1.73 (+0.02)

Curis to Release Second Quarter 2016 Financial Results and Hold Conference Call on August 4, 2016
GlobeNewswire - Thu Jul 28, 6:01AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2016 financial results on Thursday, August 4, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.
CRIS: 1.73 (+0.02)

Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 08, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that updated data from the Phase 1 trial of CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 21 Congress of the European Hematology Association to be held from June 9-12 in Copenhagen, Denmark.
CRIS: 1.73 (+0.02)

Curis to Present at the Jefferies Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:15AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President & Chief Executive Officer, will present at the Jefferies Healthcare Conference on June 8, 2016, at 2:00 p.m. Eastern Time in New York City.
CRIS: 1.73 (+0.02)

Curis Announces Presentations Related to CUDC-907 and Erivedge(R) at 2016 ASCO Annual Meeting
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that a Phase 2 trials-in-progress poster for CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from June 3-7 in Chicago, IL.
CRIS: 1.73 (+0.02)

Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints
GlobeNewswire - Wed Jun 01, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for CA-170. CA-170 is a first-in-class orally available small molecule that has been designed to target and inhibit the immune checkpoints, Programmed Death Ligand-1 (PD-L1) and V-domain Immunoglobulin Suppressor of T-cell Activation (VISTA).
CRIS: 1.73 (+0.02)

Curis to Release First Quarter 2016 Financial Results and Hold Conference Call on May 9, 2016
GlobeNewswire - Mon May 02, 6:34AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2016 financial results on Monday, May 9, 2016, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT.
CRIS: 1.73 (+0.02)

Curis Announces Presentation of Preclinical Data from CUDC-907, CA-170 and PD-L1/TIM-3 Antagonist and CA-4948 Programs at AACR Annual Meeting
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, today announced that Curis scientists and its collaborator, Aurigene will present data from multiple programs at the Annual Meeting of American Association of Cancer Research (AACR) to be held from April 16 - 20, 2016 in New Orleans, LA.
CRIS: 1.73 (+0.02)

Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology
GlobeNewswire - Mon Apr 04, 6:00AM CDT
-- Latest analysis of data presented at the American Society of Hematology's annual meeting in December, 2015 --
CRIS: 1.73 (+0.02)

Curis Announces Expansion of Executive Team
GlobeNewswire - Wed Mar 30, 6:00AM CDT
-- James Dentzer joins Curis as Chief Financial and Chief Administrative Officer --
CRIS: 1.73 (+0.02)

Global Curis, Inc. Market Latest Report Product Pipeline Review 2015 - Acute Market Reports
M2 - Fri Feb 05, 7:34AM CST
'CURIS, INC. - Product Pipeline Review - 2015', provides an overview of the CURIS, INC.'s pharmaceutical research and development focus.
CRIS: 1.73 (+0.02)

Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.73 (+0.02), IMMU: 2.74 (+0.06), INCY: 82.02 (+1.21), IMGN: 2.75 (-0.05), AMGN: 169.77 (-0.36), EPZM: 7.16 (-0.15), BIND: 0.78 (-0.09), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), CTIC: 0.39 (unch), IDRA: 1.92 (unch), CYCC: 5.71 (unch), GILD: 76.89 (-0.53), AZN: 33.31 (+0.71), ABBV: 64.12 (+0.09), CBMG: 13.94 (-0.55), CELGZ: 1.18 (+0.05)

Curis to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 3:05PM CST
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the BIO CEO & Investor Conference, February 8, 2016, at 5:30 p.m. Eastern Time in New York City.
CRIS: 1.73 (+0.02)

Follicular Lymphoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/38wlhh/follicular) has announced the addition of the "Follicular Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Follicular Lymphoma , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AbbVie Inc. - Affimed Therapeutics AG - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bio-Path Holdings, Inc. - Biocon Limited - Biogenomics Limited - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Celltrion, Inc. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Curis, Inc. - Dynavax Technologies Corporation - (30 Others) Key Topics Covered: - Introduction - Follicular Lymphoma Overview - Therapeutics Development - Pipeline Products for Follicular Lymphoma - Overview - Pipeline Products for Follicular Lymphoma - Comparative Analysis - Follicular Lymphoma - Therapeutics under Development by Companies - Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes - Follicular Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Follicular Lymphoma - Products under Development by Companies - Follicular Lymphoma - Products under Investigation by Universities/Institutes - Follicular Lymphoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/38wlhh/follicular
DVAX: 10.91 (-5.03), CRIS: 1.73 (+0.02), BPTH: 1.55 (-0.03), ABBV: 64.12 (+0.09), CTIC: 0.39 (unch), BMY: 56.35 (-0.41), CBMG: 13.94 (-0.55), CHRS: 30.81 (+0.83), CELGZ: 1.18 (+0.05)

Global Relapsed Multiple Myeloma Therapeutics Pipeline Review 2015
M2 - Thu Jan 14, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/mkmlnh/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Multiple Myeloma Overview - Therapeutics Development - Pipeline Products for Relapsed Multiple Myeloma - Overview - Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis - Relapsed Multiple Myeloma - Therapeutics under Development by Companies - Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Multiple Myeloma - Products under Development by Companies - Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes - Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development - 4SC AG - AB Science SA - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Celgene Corporation - Cellectar Biosciences, Inc. - Cleave Biosciences - Curis, Inc. - Daiichi Sankyo Company, Limited - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - IGF Oncology, LLC. - Immunomedics, Inc. - Jasco Pharmaceuticals, LLC. - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Noxxon Pharma AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. - Sanofi For more information visit http://www.researchandmarkets.com/research/mk...d_multiple
CLRB: 2.16 (+0.02), CRIS: 1.73 (+0.02), IMMU: 2.74 (+0.06), ONCY: 0.33 (-0.02), PFE: 34.77 (+0.09), AMGN: 169.77 (-0.36), GSK: 44.26 (+1.28), BMY: 56.35 (-0.41), JNJ: 119.32 (+0.24), MRK: 62.98 (+0.08), CALA: 3.08 (unch), ABBV: 64.12 (+0.09), NVS: 79.38 (+1.11), EXEL: 11.54 (+0.19), ARRY: 3.50 (-0.02), CELGZ: 1.18 (+0.05)

Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 1.73 (+0.02), TTNP: 5.55 (-0.13), GALT: 1.70 (+0.05)

Biotechnology Equity Picks - Arena Pharma, uniQure, Cytokinetics, and Curis
ACCESSWIRE - Wed Jan 06, 7:05AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2016 / Park Lane Advisor has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), uniQure N.V. (NASDAQ: QURE), Cytokinetics Inc. (NASDAQ: CYTK), and Curis Inc. (NASDAQ: CRIS). Free research report on Arena Pharma can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 05, 2016, the NASDAQ Composite ended at 4,891.43, down 0.24%, the Dow Jones Industrial Average edged 0.06% higher, to finish the day at 17,158.66, and the S&P 500 closed at 2,016.71, up 0.20%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CYTK: 10.36 (-0.14), CRIS: 1.73 (+0.02), QURE: 7.70 (unch), ARNA: 1.57 (+0.01)

Can Walgreens Boots (WBA) Retain its Earnings Streak in Q1?
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 8:00AM CST
So far, the legacy Walgreens' partnership with Alliance Boots has yielded positive results, with combined synergies totaling $799 million in fiscal 2015 for Walgreens Boots (WBA)
FATE: 2.38 (-0.07), CRIS: 1.73 (+0.02), WBA: 82.22 (+0.68), IDXX: 114.09 (+0.93)

Biotechnology Equities Ahead of Market -- Regulus Therapeutics, Ocata Therapeutics, Vanda Pharma, and Curis
ACCESSWIRE - Wed Dec 30, 7:01AM CST
NEW YORK, NY / ACCESSWIRE / December 30, 2015 / Park Lane Advisor has initiated coverage on the following equities: Regulus Therapeutics Inc. (NASDAQ: RGLS), Ocata Therapeutics Inc. (NASDAQ: OCAT), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), and Curis Inc. (NASDAQ: CRIS). Free research report on Regulus Therapeutics can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 29, 2015, the NASDAQ Composite ended at 5,107.94, up 1.33%, the Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
CRIS: 1.73 (+0.02), OCAT: 8.47 (+0.01), VNDA: 15.55 (+0.26), RGLS: 3.18 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 61

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 49

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
Align Wagner Collection Tests Men's Footwear Depth

Updated Category News Views 57

Three pairs of shoes are not a revolution, but they can expose whether a young brand has its footing. Align, established in 2025 by H.H. Brown, is rolling out the Wagner collection for Fall-Winter 2026 with a waterproof boot, a penny loafer and a lace-up oxford. That is a sensible little arsenal, not some overstuffed catalog dreamed up by a marketing committee that has...

Continue Reading
Lennar's 6.73% Slide Puts Disclosure Claims in Focus

Updated Category News Views 12

A homebuilder can survive ugly margins; murky demand signals are another beast entirely. Lennar is staring at a securities class action after a bruising run of disclosures and market reactions, and the central issue is not whether housing got tougher. Everybody with a pulse knew rates were squeezing buyers. The issue is whether NYSE:LEN gave investors a sufficiently clear...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 80

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 84

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 110

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading

Top 5 Most Recently Viewed Articles

DatChat Receives Mexican Patent for Enhanced Privacy Solutions

Updated Category News Views 157

DatChat's Latest Patent Achievement New Brunswick, NJ - DatChat, Inc. (NASDAQ: DATS), a leading company in secure messaging and social media, has exciting news to share. Recently, the Mexican Patent office issued a Notice of Allowance for DatChat's patent application titled "Systems and Methods of Transforming Electronic Content." This development follows the company...

Continue Reading
Flora Growth Partners with Canopy to Enhance Cannabis Access

Updated Category News Views 111

Flora Growth Enters the Australian Medical Cannabis Market Flora Growth Corp (NASDAQ: FLGC) has recently taken a significant step into the Australian medical cannabis arena through its strategic partnership with Canopy Growth Corp (NASDAQ: CGC). A distribution agreement has been signed, allowing Flora's subsidiary, Australian Vaporizers, to handle the distribution of...

Continue Reading
Digital Brands Group Sets Public Offering of 11.36 Million Units

Updated Category News Views 167

Digital Brands Group Projects Strong Growth with New Offering Digital Brands Group, Inc. (OTC PINK: DBGI), a unique entity known for curating luxury lifestyle brands, has recently made headlines with their announcement regarding a public offering. This initiative, which involves an impressive volume of 11.36 million units, is set to make waves in the market. Details of...

Continue Reading
Unraveling Solana's Remarkable Rise From $11 to $166

Updated Category News Views 154

Unraveling Solana's Remarkable Rise From $11 to $166 Solana (SOL), a cryptocurrency that emerged in March 2020, has astonished investors with its dramatic increase in value. It has risen more than 15 times its initial value, predominantly bolstered by a vibrant ecosystem that has flourished around various meme coins. Jim Cramer’s Warning In 2022, Jim Cramer, a prominent...

Continue Reading
LO3 Capital Revolutionizes Travel Services with CCRA Deal

Updated Category News Views 189

LO3 Capital Makes Strategic Investment in CCRA International LO3 Capital, a dynamic private investment firm, is making waves with its recent senior debt investment in CCRA International, Inc. This relationship is pivotal for CCRA, a technology-driven travel services platform, as it progresses towards acquiring ABC Global Services. This acquisition is set to form one of...

Continue Reading